Peter C. Lucas

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract A033: Inhibitors of GRK2-targeting-microRNAs: New therapeutic strategies for MALT1-dependent lymphomas

  Blood Cancer Discovery · 2026-06-24

• A report of thirteen non-conventional FLCN-mutated (renal) tumors (FMT) and a discussion of proposed diagnostic criteria, convergent FLCN/TFEB and FLCN/MITF E318K signaling, and FLCN immunohistochemistry

  Human Pathology · 2026-06-18

• EWSR1-rearranged renal neoplasia: Clinicopathologic and molecular characterization of 39 cases from a single institution

  Human Pathology · 2026-04-30

• Abstract 2061: MicroRNAs targeting tumor suppressor GRK2: Novel potential therapeutic strategies for restraining MALT1-dependent DLBCL.

  Cancer Research · 2026-04-03

• Abstract 7392: A cancer cell-intrinsic PAR1/MALT1/PD-L1 signaling pathway drives immune evasion in triple-negative breast cancer

  Cancer Research · 2026-04-03

• Abstract 94: Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors.

  Cancer Research · 2026-04-03

• Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-03-18 · 1 citations

• Abstract B046: The GPCR-MALT1 protease signaling axis drives an immunosuppressive secretome in triple-negative breast cancer

  Cancer Immunology Research · 2026-02-18

• Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency)

  Mayo Clinic Proceedings · 2026-02-01 · 1 citations

• Supplementary Figure S3 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Supplementary Figure S6 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Supplementary Figure S5 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Supplementary Figure S1 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Supplementary Table S2 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Supplementary Table S1 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Supplementary Figure S2 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Supplementary Figure S4 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

  2025-11-25

• Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer

  Journal of Clinical Oncology · 2025-10-02

• MicroRNAS DOWNREGULATE TUMOR SUPPRESSOR GRK2 IN MALT1-DEPENDENT DIFFUSE LARGE B-CELL LYMPHOMA

  Leukemia Research · 2025-09-01

• p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy

  Nature Cancer · 2025-06-27 · 11 citations